CSF2 and breast cancer: The final analysis of the randomized phase II trial of AE37 + GM-CSF vaccine verses GM-CSF alone for the prevention of breast cancer recurrence in node-positive or high-risk, node negative patients, showed no significant differences in the 5-year disease-free survival (DFS) between treatment arms.